LEVAMISOLE IN ADVANCED HUMAN BREAST CANCER

A.F. Rojas(Instituto de Oncología de Rosario), A Olivari(Instituto de Oncología de Rosario), H. Glait(Instituto de Oncología de Rosario), E. Mickiewicz(University of Chicago), J.N. Feierstein(Instituto de Oncología de Rosario)
The Lancet
January 1, 1976
10.1016/s0140-6736(76)91337-4
Cited by 159

Related Papers

A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer
|New England Journal of Medicine|2004|1.8k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
|The Lancet|2007|912
Activity of Exemestane in Metastatic Breast Cancer After Failure of Nonsteroidal Aromatase Inhibitors: A Phase II Trial
|Journal of Clinical Oncology|2000|318
Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation
|Annals of Oncology|2009|152